143 related articles for article (PubMed ID: 34919635)
21. Management and treatment of Andersen-Tawil syndrome (ATS).
Sansone V; Tawil R
Neurotherapeutics; 2007 Apr; 4(2):233-7. PubMed ID: 17395133
[TBL] [Abstract][Full Text] [Related]
22. Andersen-Tawil syndrome: report of 3 novel mutations and high risk of symptomatic cardiac involvement.
Kostera-Pruszczyk A; Potulska-Chromik A; Pruszczyk P; Bieganowska K; Miszczak-Knecht M; Bienias P; Szczałuba K; Lee HY; Quinn E; Ploski R; Kaminska A; Ptáček LJ
Muscle Nerve; 2015 Feb; 51(2):192-6. PubMed ID: 24861851
[TBL] [Abstract][Full Text] [Related]
23. Andersen-Tawil Syndrome: A Comprehensive Review.
Pérez-Riera AR; Barbosa-Barros R; Samesina N; Pastore CA; Scanavacca M; Daminello-Raimundo R; de Abreu LC; Nikus K; Brugada P
Cardiol Rev; 2021 Jul-Aug 01; 29(4):165-177. PubMed ID: 32947483
[TBL] [Abstract][Full Text] [Related]
24. Genotype-phenotype correlations of KCNJ2 mutations in Japanese patients with Andersen-Tawil syndrome.
Haruna Y; Kobori A; Makiyama T; Yoshida H; Akao M; Doi T; Tsuji K; Ono S; Nishio Y; Shimizu W; Inoue T; Murakami T; Tsuboi N; Yamanouchi H; Ushinohama H; Nakamura Y; Yoshinaga M; Horigome H; Aizawa Y; Kita T; Horie M
Hum Mutat; 2007 Feb; 28(2):208. PubMed ID: 17221872
[TBL] [Abstract][Full Text] [Related]
25. Hypokalemic periodic paralysis, facial dysmorphism and ventricular arrhythmia (clinical triad of Andersen-Tawil syndrome).
Thakkar M; Biswas TK; Desle HB
J Assoc Physicians India; 2012 Nov; 60():56-8. PubMed ID: 23767205
[TBL] [Abstract][Full Text] [Related]
26. Molecular stratification of arrhythmogenic mechanisms in the Andersen Tawil syndrome.
Moreno-Manuel AI; Gutiérrez LK; Vera-Pedrosa ML; Cruz FM; Bermúdez-Jiménez FJ; Martínez-Carrascoso I; Sánchez-Pérez P; Macías Á; Jalife J
Cardiovasc Res; 2023 May; 119(4):919-932. PubMed ID: 35892314
[TBL] [Abstract][Full Text] [Related]
27. Andersen-Tawil syndrome with early fixed myopathy.
Lefter S; Hardiman O; Costigan D; Lynch B; McConville J; Hand CK; Ryan AM
J Clin Neuromuscul Dis; 2014 Dec; 16(2):79-82. PubMed ID: 25415519
[TBL] [Abstract][Full Text] [Related]
28. Identification and functional characterisation of a novel KCNJ2 mutation, Val302del, causing Andersen-Tawil syndrome.
Ördög B; Hategan L; Kovács M; Seprényi G; Kohajda Z; Nagy I; Hegedűs Z; Környei L; Jost N; Katona M; Szekeres M; Forster T; Papp JG; Varró A; Sepp R
Can J Physiol Pharmacol; 2015 Jul; 93(7):569-75. PubMed ID: 26103554
[TBL] [Abstract][Full Text] [Related]
29. Characterization of a novel, dominant negative KCNJ2 mutation associated with Andersen-Tawil syndrome.
Marrus SB; Cuculich PS; Wang W; Nerbonne JM
Channels (Austin); 2011; 5(6):500-9. PubMed ID: 22186697
[TBL] [Abstract][Full Text] [Related]
30. Non dominant-negative KCNJ2 gene mutations leading to Andersen-Tawil syndrome with an isolated cardiac phenotype.
Limberg MM; Zumhagen S; Netter MF; Coffey AJ; Grace A; Rogers J; Böckelmann D; Rinné S; Stallmeyer B; Decher N; Schulze-Bahr E
Basic Res Cardiol; 2013 May; 108(3):353. PubMed ID: 23644778
[TBL] [Abstract][Full Text] [Related]
31. [Andersen syndrome: a particular form of paralysis with cardiac dysrhythmia].
Pouget J; Philip N; Faugere G; Pellissier JF
Rev Neurol (Paris); 2004 May; 160(5 Pt 2):S38-42. PubMed ID: 15269659
[TBL] [Abstract][Full Text] [Related]
32. Trafficking-competent and trafficking-defective KCNJ2 mutations in Andersen syndrome.
Ballester LY; Benson DW; Wong B; Law IH; Mathews KD; Vanoye CG; George AL
Hum Mutat; 2006 Apr; 27(4):388. PubMed ID: 16541386
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations.
Miyamoto K; Aiba T; Kimura H; Hayashi H; Ohno S; Yasuoka C; Tanioka Y; Tsuchiya T; Yoshida Y; Hayashi H; Tsuboi I; Nakajima I; Ishibashi K; Okamura H; Noda T; Ishihara M; Anzai T; Yasuda S; Miyamoto Y; Kamakura S; Kusano K; Ogawa H; Horie M; Shimizu W
Heart Rhythm; 2015 Mar; 12(3):596-603. PubMed ID: 25496985
[TBL] [Abstract][Full Text] [Related]
34. [Andersen-Tawil syndrome. Efficacy of class IC drugs].
Makarov LM; Komoliatova VN; Kolosov VO; Fedina NN; Solokhin IuA
Kardiologiia; 2013; 53(1):91-6. PubMed ID: 23548357
[TBL] [Abstract][Full Text] [Related]
35. Functional and clinical characterization of a mutation in KCNJ2 associated with Andersen-Tawil syndrome.
Lu CW; Lin JH; Rajawat YS; Jerng H; Rami TG; Sanchez X; DeFreitas G; Carabello B; DeMayo F; Kearney DL; Miller G; Li H; Pfaffinger PJ; Bowles NE; Khoury DS; Towbin JA
J Med Genet; 2006 Aug; 43(8):653-9. PubMed ID: 16571646
[TBL] [Abstract][Full Text] [Related]
36. Andersen-Tawil syndrome: prospective cohort analysis and expansion of the phenotype.
Yoon G; Oberoi S; Tristani-Firouzi M; Etheridge SP; Quitania L; Kramer JH; Miller BL; Fu YH; Ptácek LJ
Am J Med Genet A; 2006 Feb; 140(4):312-21. PubMed ID: 16419128
[TBL] [Abstract][Full Text] [Related]
37. Andersen-Tawil Syndrome With Novel Mutation in
Yim J; Kim KB; Kim M; Lee GD; Kim M
Front Pediatr; 2021; 9():790075. PubMed ID: 35174115
[TBL] [Abstract][Full Text] [Related]
38. Andersen-Tawil Syndrome Presenting with Complete Heart Block.
Suetterlin K; Männikkö R; Flossmann E; Sud R; Fialho D; Vivekanandam V; James N; Gossios TD; Hanna MG; Savvatis K; Matthews E
J Neuromuscul Dis; 2021; 8(1):151-154. PubMed ID: 33074188
[TBL] [Abstract][Full Text] [Related]
39. Andersen cardiodysrhythmic periodic paralysis with KCNJ2 mutations: a novel mutation in the pore selectivity filter residue.
Lim BC; Kim GB; Bae EJ; Noh CI; Hwang H; Kim KJ; Hwang YS; Ko TS; Chae JH
J Child Neurol; 2010 Apr; 25(4):490-3. PubMed ID: 20382953
[TBL] [Abstract][Full Text] [Related]
40. Clinical and neurophysiological variability in Andersen-Tawil syndrome.
Kokubun N; Aoki R; Nagashima T; Komagamine T; Kuroda Y; Horie M; Hirata K
Muscle Nerve; 2019 Dec; 60(6):752-757. PubMed ID: 31509255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
